BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22702968)

  • 1. Leukaemic transformation with romiplostim.
    Gardner K; Mathe S; Sahu S
    Br J Haematol; 2012 Jul; 158(2):153. PubMed ID: 22702968
    [No Abstract]   [Full Text] [Related]  

  • 2. Romiplostim: leukaemia after myelodysplastic syndromes.
    Prescrire Int; 2012 May; 21(127):129. PubMed ID: 22844683
    [No Abstract]   [Full Text] [Related]  

  • 3. Progression of romiplostim myelofibrosis to myeloproliferative neoplasm.
    Dadfarnia T; Lee S
    Blood; 2014 Mar; 123(13):1987. PubMed ID: 24800303
    [No Abstract]   [Full Text] [Related]  

  • 4. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
    Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
    Prica A; Sholzberg M; Buckstein R
    Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim-induced myelofibrosis.
    Rashidi A; Roullet MR
    Blood; 2013 Sep; 122(12):2001. PubMed ID: 24175353
    [No Abstract]   [Full Text] [Related]  

  • 8. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.
    Dultz G; Kronenberger B; Azizi A; Mihm U; Vogl TJ; Sarrazin U; Sarrazin C; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Jul; 55(1):229-32. PubMed ID: 21310200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia.
    Oshima Y; Yuji K; Tanimoto T; Hinomura Y; Tojo A
    Intern Med; 2013; 52(19):2193-201. PubMed ID: 24088751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 11. Romiplostim-induced erythromelalgia in a patient with idiopathic thrombocytopenic purpura.
    Kluger N; Bessis D; Quittet P; Rigau V; Guillot B; Girard C
    Br J Dermatol; 2009 Aug; 161(2):482-4. PubMed ID: 19486002
    [No Abstract]   [Full Text] [Related]  

  • 12. Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia.
    Ho P; Khan S; Crompton D; Hayes L
    Intern Med J; 2015 Jun; 45(6):682-3. PubMed ID: 26059883
    [No Abstract]   [Full Text] [Related]  

  • 13. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
    Prescrire Int; 2009 Dec; 18(104):246. PubMed ID: 20020571
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
    Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
    Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
    Leung T; Lokan J; Turner P; Smith C
    Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
    [No Abstract]   [Full Text] [Related]  

  • 18. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
    Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
    Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
    Polverelli N; Catani L; Sollazzo D; Vianelli N; Palandri F
    Ann Hematol; 2015 Feb; 94(2):339-41. PubMed ID: 24994539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.